Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
Chief Justice of India DY Chandrachud on Sunday said that due to an overburdened healthcare system, coupled with increasing commercialisation of healthcare, mistrust and suspicion on medical services are becoming narratives surrounding healthcare. The Chief Justice said, "We as a society need to counteract structural and policy constraint which prevent access to good healthcare in order to achieve healthcare justice", while lamenting that growing socio-economic inequalities in India have a disproportionate effect on health outcomes of marginalized groups. Speaking at the 19th Sir Ganga Ram Oration on Prescription for Justice- 'Quest for Fairness and Equity in Healthcare', the CJI said equality and fairness are prime factors that permeate the healthcare system to facilitate justice. "Due to an overburdened healthcare system, coupled with increasing commercialization of healthcare, mistrust and suspicion on medical services are becoming narratives surrounding healthcare. I began by ..
India's COVID-19 tally rose by 128 in a day while active cases have declined to 1,763, according to the Union Health Ministry data updated on Thursday. The death toll stands at 5,30,741 with one death reported from Uttar Pradesh, the data updated at 8 am stated. The total tally of Covid cases was recorded at 4.46 crore (4,46,83,023). The daily positivity was recorded at 0.09 per cent while the weekly positivity was pegged at 0.08 per cent. Active cases now comprise 0.01 per cent of the total infections, while the national COVID-19 recovery rate has increased to 98.81 per cent, according to the health ministry website. The number of people who have recuperated from the disease surged to 4,41,50,519, while the case fatality rate was recorded at 1.19 per cent. According to the ministry's website, 220.52 crore doses of Covid vaccine have been administered in the country so far under the nationwide COVID-19 vaccination drive. India's COVID-19 tally crossed the 20-lakh mark on August
Lymphatic filariasis is not a neglected disease for India as may be the case in some other countries but is a priority for elimination in a time-bound manner, Union Health Minister Mansukh Mandaviya said Friday. Inaugurating the National Symposium on India's Roadmap to Eliminate Lymphatic Filariasis here, he reiterated India's commitment towards the target of eradicating the disease from the country by end of 2027. As part of its commitment to eliminate the disease by end of 2027, the health ministry has come up with a renewed five-pronged strategy as part of which multi-drug administration (MDA) will be held twice a year in synchronisation with National Deworming Day on February 10 and August 10, Mandaviya said. The other aspects of the strategy include early diagnosis and treatment; engagement of medical colleges for strengthening morbidity management and disability services; integrated vector control with multi-sectoral coordinated efforts; inter-sectoral convergence with allied
The Supreme Court Friday directed the Centre and the states to file their responses on a plea seeking directions for a uniform standard of healthcare for citizens in line with the Constitution by adopting provisions of the Clinical Establishments Act, 2010. A bench of Justices B R Gavai and Vikram Nath granted four weeks to the Union of India and the state governments to file their replies. The top court was hearing a plea filed by Jan Swasthya Abhiyan, Patients' Rights Campaign and K M Gopakumar which had also sought directions for operationalising all the provisions of the Act, as well as Clinical Establishment Rules, 2012 in order to ensure affordable and quality healthcare. The plea had sought directions for notification and implementation of the conditions for registration of clinical establishments such as observance of minimum standards, display of rates for procedures and services, compliance with the standard treatment protocol, as provided in Sections 11 and 12 of the CEA
Drug firm Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for Lurasidone Hydrochloride tablets, used to treat bipolar depression. The approved product is therapeutically equivalent to the reference listed drug product (RLD) Latuda tablets of Sunovion Pharmaceuticals Inc. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Lurasidone Hydrochloride tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Alembic Pharmaceuticals said in a regulatory filing. Quoting IQVIA data, Alembic Pharma said Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg have an estimated market size of USD 3.7 billion for the twelve months ending December 2020. Lurasidone Hydrochloride tablets are indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Alembic Pharma said it has settled the cas